Understanding Medicare’s Medically Unlikely Edits
Allergists should be aware of the following MUEs associated with commonly billed CPT codes and the following MUE Adjudication Indicators.
New proposed Medicare drug pricing models are unveiled
The College emphasizes that while fair pricing is essential, policies mustn't compromise drug availability or stifle research into new therapies.
2027 Medicare price reductions for asthma inhalers
CMS unveiled agreements with drug makers for sharply lower prices on 15 high-cost medications under Medicare's drug negotiation program.
Advocacy Council responds to the Proposed 2026 Medicare Physician Fee Schedule
The College’s Advocacy Council submitted formal comments to CMS on the 2026 Medicare Physician Fee Schedule proposed rule.
House committee hearing signals scrutiny ahead for Medicare Advantage
Lawmakers on both sides of the aisle expressed frustration with the current state of the Medicare Advantage (MA) program.
The College supports the CPT definition of a “dose”
We explained the background of immunotherapy and the confusion that can arise when two definitions describe the same procedure.
Traditional MIPS or MVP for allergists in 2025?
This article provides an overview of current MVP reporting options and considerations for allergists.
College launches Payer Education Campaign to halt AIT audits and claims denials
The College is proud to announce the Payer Education Campaign (PEC) that focuses on claims for allergen immunotherapy services.
2025 Medicare Physician Fee Schedule Final Rule
This article summarizes key proposals concerning the Medicare Physician Fee Schedule that impact allergy practices.
How do MACs impact patients
To process Medicare claims, MACs are awarded geographic jurisdictions in which they serve as primary contacts
… results in Medicare and Advocacy Resources.
